Form D · Pharmaceuticals
Reset Pharmaceuticals, Inc.
New York, NY · CIK 0001905880
Offering snapshot reported Feb 25, 2022 · SEC filing
- Reported sold
- $11.1M Offering amount: $12.7M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Nov 26, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 25, 2022 | Initial | $11,115,105 | No comparison | 26 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-435097
Source: Form D, filed Feb 25, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Andreadis | Director, Executive |
| Jan Anders Karlsson | Director, Executive |
| Tim Schlidt | Director |
| Philip Taub | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
241 Central Park W Apt 9 A
New York, NY, 10024
New York, NY, 10024